United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - precose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. precose is contraindicated in patients with known hypersensitivity to the drug. precose is contraindicated in patients with diabetic ketoacidosis or cirrhosis. precose is also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, precose is contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - precose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. precose is contraindicated in patients with known hypersensitivity to the drug. precose is contraindicated in patients with diabetic ketoacidosis or cirrhosis. precose is also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, precose is contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 50 mg - precose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. precose is contraindicated in patients with known hypersensitivity to the drug. precose is contraindicated in patients with diabetic ketoacidosis or cirrhosis. precose is also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, precose is contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

Bangladesh - English - DGDA (Directorate General of Drug Administration)

kemiko pharmaceuticals ltd. - acarbose - tablet - 100 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

kemiko pharmaceuticals ltd. - acarbose - tablet - 50 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - acarbose - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - acarbose - oral tablet - 50mg

Ireland - English - HPRA (Health Products Regulatory Authority)

multigeneris gmbh - acarbose - tablets - 50 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

multigeneris gmbh - acarbose - tablets - 100 milligram

Israel - English - Ministry of Health

rafa laboratories ltd - acarbose - tablets - acarbose 50 mg - acarbose - acarbose - treatment of non-insulin dependent diabetes mellitus (niddm) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.